2-((4-ethylphenyl)thio)ethan-1-amine | 871683-85-1

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-((4-ethylphenyl)thio)ethan-1-amine
• 英文别名: 2-(4-ethyl-phenylsulfanyl)-ethylamine；2-(4-ethylphenyl)sulfanylethanamine
• CAS: 871683-85-1
• 化学式: C₁₀H₁₅NS
• mdl: MFCD11585789
• 分子量: 181.302
• InChiKey: XDPKQNGBWJVANJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  51.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-((4-ethylphenyl)thio)ethan-1-amine 、 2-((5-(2-hydroxyphenyl)-4H-1,2,4-triazol-3-yl)thio)acetic acid 在 N-甲基吗啉 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以52 %的产率得到N-(2-((4-ethylphenyl)thio)ethyl)-2-((5-(2-hydroxyphenyl)-4H-1,2,4-triazol-3-yl)thio)acetamide
  参考文献：
  名称：

  并非所有命中鉴定技术都适用于 1-脱氧-d-木酮糖 5-磷酸合酶 (DXPS)：充分利用虚拟筛选活动

  摘要：

  药物发现中的命中鉴定并不总是直截了当：针对结核分枝杆菌1-脱氧-d-木酮糖 5-磷酸合酶 (DXPS) 的虚拟筛选并未产生合适的中靶命中，但针对病原菌的测试显示有希望的生长抑制一类化合物的革兰氏阴性大肠杆菌。建立稳健的合成路线使对衍生物的快速研究成为可能，并开辟了新的研究方向。

  DOI：

  10.1002/cmdc.202200590
• 作为产物：
  描述：

  2-唑烷酮 、 4-乙基苯硫酚 在 sodium ethanolate 作用下， 以 异丙醇 为溶剂， 以25 %的产率得到2-((4-ethylphenyl)thio)ethan-1-amine
  参考文献：
  名称：

  并非所有命中鉴定技术都适用于 1-脱氧-d-木酮糖 5-磷酸合酶 (DXPS)：充分利用虚拟筛选活动

  摘要：

  药物发现中的命中鉴定并不总是直截了当：针对结核分枝杆菌1-脱氧-d-木酮糖 5-磷酸合酶 (DXPS) 的虚拟筛选并未产生合适的中靶命中，但针对病原菌的测试显示有希望的生长抑制一类化合物的革兰氏阴性大肠杆菌。建立稳健的合成路线使对衍生物的快速研究成为可能，并开辟了新的研究方向。

  DOI：

  10.1002/cmdc.202200590

文献信息

• [EN] PHOSPHINYL AMIDINE COMPOUNDS, METAL COMPLEXES, CATALYST SYSTEMS, AND THEIR USE TO OLIGOMERIZE OR POLYMERIZE OLEFINS<br/>[FR] COMPOSÉS DE PHOSPHINYLAMIDINE, COMPLEXES DE MÉTAL, SYSTÈMES DE CATALYSEUR, ET LEUR UTILISATION POUR OLIGOMÉRISER OU POLYMÉRISER DES OLÉFINES
  申请人：CHEVRON PHILLIPS CHEMICAL CO

  公开号：WO2011082192A1

  公开（公告）日：2011-07-07

  N2-phosphinyl amidine compounds, N2-phosphinyl amidinates, N2-phosphinyl amidine metal salt complexes, N2-phosphinyl amidinate metal salt complexes are described. Methods for making N2-phosphinyl amidine compounds, N2-phosphinyl amidinates, N2-phosphinyl amidine metal salt complexes, and N2-phosphinyl amidinate metal salt complexes are also disclosed. Catalyst systems utilizing the N2-phosphinyl amidine metal salt complexes and N2-phosphinyl amidinate metal salt complexes are also disclosed along with the use of the N2-phosphinyl amidine compounds, N2-phosphinyl amidinates, N2-phosphinyl amidine metal salt complexes, and N2-phosphinyl amidinate metal salt complexes for the oligomerization and/or polymerization of olefins.

  描述了N2-膦胺化合物、N2-膦胺酸盐、N2-膦胺金属盐络合物、N2-膦胺酸盐金属盐络合物。还公开了制备N2-膦胺化合物、N2-膦胺酸盐、N2-膦胺金属盐络合物和N2-膦胺酸盐金属盐络合物的方法。还公开了利用N2-膦胺金属盐络合物和N2-膦胺酸盐金属盐络合物的催化剂系统，以及利用N2-膦胺化合物、N2-膦胺酸盐、N2-膦胺金属盐络合物和N2-膦胺酸盐金属盐络合物进行烯烃的寡聚和/或聚合的用途。
• Substituted heteroaryl- and phenylsulfamoyl compounds
  申请人：Hamanaka S. Ernest

  公开号：US20050288340A1

  公开（公告）日：2005-12-29

  The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.

  本发明涉及取代杂环芳基和苯基磺酰胺化合物，包含这些化合物的制药组合物和将这些化合物用作过氧化物酶增殖剂受体（PPAR）激动剂。PPARα激动剂，包含这些化合物的制药组合物，以及将这些化合物用于提高某些血浆脂质水平，包括高密度脂蛋白胆固醇和降低其他某些血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，因此治疗由低高密度脂蛋白胆固醇水平和/或高低密度脂蛋白胆固醇和甘油三酯水平加重的疾病，例如动脉粥样硬化和心血管疾病，在哺乳动物中，包括人类。这些化合物还可用于治疗反能量平衡（NEB）和反刍动物相关疾病。
• Substituted Heteroaryl- and Phenylsulfamoyl Compounds
  申请人：Hamanaka S. Ernest

  公开号：US20060229363A1

  公开（公告）日：2006-10-12

  The present invention is directed at substituted heteroaryl and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.

  本发明涉及取代杂环芳基和苯基磺酰胺化合物、含有该类化合物的药物组合物及其作为过氧化物酶体增殖物激活受体（PPAR）激动剂的用途。该化合物可以作为PPARα激动剂，含有该类化合物的药物组合物可用于提高某些血浆脂质水平，包括高密度脂蛋白胆固醇，并降低其他某些血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，从而治疗低高密度脂蛋白胆固醇水平和/或高低密度脂蛋白胆固醇和甘油三酯水平加剧的疾病，如动脉硬化和心血管疾病，在哺乳动物，包括人类中使用。该化合物还可用于治疗反能量平衡（NEB）和反刍动物相关疾病。
• Diimine metal complexes, methods of synthesis, and method of using in oligomerization and polymerization
  申请人：Small L. Brooke

  公开号：US20070112150A1

  公开（公告）日：2007-05-17

  Novel α-diimine metal complexes, particularly iron complexes, having a phenyl sulfidyl or substituted phenyl sulfidyl metal complexing group are disclosed. The α-diimine metal complexes having a phenyl sulfidyl or substituted phenyl sulfidyl metal complexing group are produced by forming one of the α-diimine metal complex imine bonds in the presence of a metal salt or an α-acylimine metal complex. The α-diimine metal complexes having phenyl sulfidyl or substituted phenyl sulfidyl metal complexing group are useful for polymerizing or oligomerizing olefins.

  本发明揭示了一种具有苯基硫醇或取代苯基硫醇金属配位基团的新型α-二亚胺金属配合物，特别是铁配合物。该α-二亚胺金属配合物具有苯基硫醇或取代苯基硫醇金属配位基团，是通过在金属盐或α-酰基亚胺金属配合物存在下形成α-二亚胺金属配合物亚胺键之一来制备的。具有苯基硫醇或取代苯基硫醇金属配位基团的α-二亚胺金属配合物对于聚合或寡聚烯烃非常有用。
• SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS
  申请人：HAMANAKA S. ERNEST

  公开号：US20080090829A1

  公开（公告）日：2008-04-17

  The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.

  本发明涉及取代杂环芳基和苯基磺酰胺化合物，含有这种化合物的药物组合物以及将这种化合物用作过氧化物酶体增殖物激活受体（PPAR）激动剂。PPARα激动剂，含有这种化合物的药物组合物以及使用这种化合物升高某些血浆脂质水平，包括高密度脂蛋白胆固醇并降低其他某些血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，并因此治疗低密度脂蛋白胆固醇和/或高甘油三酯水平加重的疾病，如动脉粥样硬化和心血管疾病，在哺乳动物中，包括人类。这些化合物还可用于治疗反能量平衡（NEB）和反刍动物相关疾病。